NASDAQ: ORKAOruka Therapeutics Inc Stock
$15.26-0.14 (-0.91%)
Updated Sep 15, 2025
ORKA Price
$15.26
Fair Value Price
$3.61
Market Cap
$571.50M
52 Week Low
$5.49
52 Week High
$31.13
P/E
-138.73x
P/B
1.66x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$99.98M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
-$98M
Beta
0.65
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ORKA Overview
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ORKA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ORKA
Ranked#338 of 478
Ranked#338 of 478
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.40 | A | |
| $37.30 | A | |
| $7.70 | A |
Be the first to know about important ORKA news, forecast changes, insider trades & much more!
ORKA News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ORKA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ORKA ($15.26) is overvalued by 322.73% relative to our estimate of its Fair Value price of $3.61 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ORKA ($15.26) is not significantly undervalued (322.73%) relative to our estimate of its Fair Value price of $3.61 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ORKA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ORKA due diligence checks available for Premium users.
Valuation
ORKA fair value
Fair Value of ORKA stock based on Discounted Cash Flow (DCF)
Price
$15.26
Fair Value
$3.61
Overvalued by
322.73%
ORKA ($15.26) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ORKA ($15.26) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ORKA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ORKA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-138.73x
Industry
-100.7x
Market
37.32x
ORKA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.66x
Industry
4.65x
ORKA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ORKA's financial health
Profit margin
Revenue
$0.0
Net Income
-$24.6M
Profit Margin
0%
ORKA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$357.4M
Liabilities
$13.8M
Debt to equity
0.04
ORKA's short-term assets ($332.01M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ORKA's short-term assets ($332.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ORKA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ORKA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$23.1M
Investing
$4.9M
Financing
$109.0k
ORKA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ORKA vs Biotech Stocks
Oruka Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.